Here, we discuss about the current generations of MAPK inhibitors targeting mitogen-activated protein kinase kinase/extracellular signal-regulated protein kinases (MEK/ERK), c-Jun N-terminal kinases (JNK), and p38 mitogen-activated protein kinases (p38 MAPK), as well as the means through which they may cooperate with cancer immunotherapy. This evidence concerns the gene MAPK14 and cancer.